( BRANFORD Conn.--(BUSINESS WIRE)--Jun 1...)Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting,Health

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, were presented today at the SLEEP 2007 Annual Meeting of the Associated Professional Sleep Societies (APSS) in Minneapolis, Minnesota. Two Phase 2b clinical studies with NG2-73 in chronic insomnia patients are currently being conducted by the Company. Data presented at the APSS meeting today includes the following:

"Safety and Tolerability in Early Phase I Studies of NG2-73, a Novel GABA(A) Sleep Agent"

NG2-73 is a GABA(A) receptor partial agonist which is alpha-3 subunit preferring. In vivo animal experiments suggest that NG2-73 will be a potent sedative hypnotic and may have an improved side effect profile compared to zolpidem, with respect to ethanol interaction and learning and memory at equipotent hypnotic doses.

The first-in-human studies included a single ascending dose and a five day multiple dose study in healthy subjects. The single ascending dose study started at 0.1 mg of NG2-73 and was planned to ascend to 100 mg of NG2-73 as a powder in a bottle formulation. The multiple ascending dose study was designed to test five days of once per day administration of 5, 10 and 20 mg tablets of NG2-73.

In the single ascending dose study, 48 subjects were enrolled (38 male and 10 female); all 48 subjects completed the study. Doses administered ranged from 0.1 to 60 mg. The 60 mg dose proved to be the maximum tolerated dose, as defined by the depth of sedation. The time to maximum concentration (Tmax) ranged from 0.33 to 3 hours and the half-life (T1/2) was 1.1 to 1.4 hours for all dosage groups. NG2-73 exhibited linear increases in maximum concentration (Cmax) and area under-the-curve (AUC, 0-inf) with increasing doses.

In the multiple ascending dose study, 32 subjec
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results